Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Pohl

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Rheumatology|May 3, 2017
An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working GroupMonika E Finger, Annelies Boonen, Thasia G Woodworth, et al.
The Journal of Rheumatology|August 17, 2017
Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop ReportSusan J Bartlett, Skye P Barbic, Vivian P Bykerk, et al.
The Journal of Rheumatology|June 17, 2015
Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome MeasuresJennifer Petkovic, Jonathan Epstein, Rachelle Buchbinder, et al.
Brain Imaging and Behavior|August 30, 2018
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometryKerstin Bendfeldt, Bernd Taschler, Laura Gaetano, et al.
The Journal of Rheumatology|April 17, 2015
Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision MakingKarine Toupin-April, Jennifer Barton, Liana Fraenkel, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
The Journal of Rheumatology|February 17, 2017
Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest GroupJennifer Petkovic, Jennifer L Barton, Caroline Flurey, et al.
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The Journal of Rheumatology|August 3, 2017
Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus MeetingKarine Toupin-April, Jennifer Barton, Liana Fraenkel, et al.
Clinical and Experimental Rheumatology|October 21, 2014
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programKathrine Lederballe Grøn, Lykke Midtbøll Ornbjerg, Merete Lund Hetland, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Rheumatology|May 3, 2017
An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working GroupMonika E Finger, Annelies Boonen, Thasia G Woodworth, et al.
The Journal of Rheumatology|August 17, 2017
Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop ReportSusan J Bartlett, Skye P Barbic, Vivian P Bykerk, et al.
The Journal of Rheumatology|June 17, 2015
Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome MeasuresJennifer Petkovic, Jonathan Epstein, Rachelle Buchbinder, et al.
Brain Imaging and Behavior|August 30, 2018
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometryKerstin Bendfeldt, Bernd Taschler, Laura Gaetano, et al.
The Journal of Rheumatology|April 17, 2015
Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision MakingKarine Toupin-April, Jennifer Barton, Liana Fraenkel, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
The Journal of Rheumatology|February 17, 2017
Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest GroupJennifer Petkovic, Jennifer L Barton, Caroline Flurey, et al.
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The Journal of Rheumatology|August 3, 2017
Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus MeetingKarine Toupin-April, Jennifer Barton, Liana Fraenkel, et al.
Clinical and Experimental Rheumatology|October 21, 2014
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programKathrine Lederballe Grøn, Lykke Midtbøll Ornbjerg, Merete Lund Hetland, et al.
Pageof 7